Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensipar in secondary hyperparathyroidism and chronic renal insufficiency
NCT00042432Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2002
- Primary completion
- Mar 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) comparing Cinacalcet with Placebo (2 arms). Primary endpoint: Reduction in Mean iPTH of ≥ 30% at 18 weeks. Started Jun 2002; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00042432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042432.